Videos

Kyle Wood, MD, reviews data and clinical implications for the use of reloxaliase in enteric hyperoxaluria as seen in the phase 3 URIROX-1 trial and shares insight on additional ongoing trials.

Ashley E. Ross, MD, PhD, leads the discussion on risk stratification in advanced prostate cancer and approaching prostate cancer screening.

Bobby Liaw, MD; Neal Shore, MD, FACS; and Vivek K. Narayan, MD, MS, discuss the incidence and prevalence of advanced prostate cancer, including mCSPC and nmCRPC.

“While this study does offer a lot of promise for the treatment options that we can offer to these patients, it does also highlight the need for further prospective trials to evaluate the efficacy of this treatment, as well as the treatments of all the different surgical options available to patients who are suffering from BPH,” says Evan Garden.

“There's unquestionably a real signal for…agents that are well tolerated that can be given for a long period of time,” says Sam S. Chang, MD, MBA.

“It is a promising drug in terms of the 3-month complete response rate,” says Chad Ritch, MD, MBA, FACS.

“I would say what RTOG-0815 has provided is data to have an intelligent conversation with our patients and provide them numbers so that they know what to expect,” says Bridget F. Koontz, MD.

“I think the key elements are that you should know about Aquablation if you are treating BPH in consideration for your patients and care, especially those who are looking for a more durable response and to maintain their ejaculation,” says Kevin Zorn, MD, FRCSC, FACS.

“New things are being developed and, I believe, at the moment showing great initiative and resolve,” says Justin Chee, MD.

Daniel P. Petrylak, MD, leads the discussion on approaching treatment of high-volume metastatic castration-naïve prostate cancer.

A panel of experts in prostate cancer examine the use of conventional imaging and PSMA PET/CT and the impact on their approach to the management of mCNPC.

“We need better tests and better biomarkers to try to determine who still has residual cancer, even though they look like they don't,” says Christopher B. Anderson, MD, MPH.

Welcome to another installment of Uranimals, our video series featuring urologists and their pets. From a dog duo to a group of animals living mountainside, check out our latest guests!

“Our preclinical therapy models all show us that the combination of the 2 agents [alpha and beta particles] is substantially superior to either agent alone,” says Neil H. Bander, MD.

“Fortunately, since things have…eased up with the pandemic, I would say probably in the last 6 months I've noticed that the BCG availability has improved,” says Chad R. Ritch, MD, MBA, FACS.

“Thirteen percent of all doctors have suicidal ideation, and more than [400 physicians per year] will complete suicide. That is a tragedy of medicine,” says Diana Londoño, MD.

“I believe that at every stage, it's very important that we focus on healthful lifestyle behaviors because we can improve [urologic patients’] overall survival and their cardiovascular health,” says Stacy Loeb, MD, PhD, MSc.

“I think it's important for people to recognize this revolution that's going on, to see that we're going from what fell to why it fell,” says John O. L. DeLancey, MD.

“Compared to other BPH treatments, this is a very fast, reproducible technology that could democratize how all urologists do BPH surgery,” says Kevin Zorn, MD, FRCSC, FACS.

“It was black, it was overwhelming, it was every day,” says William Lynes, MD.

Dr Raoul S. Concepcion presents the case of a 69-year-old man with metastatic castration-naïve prostate cancer (mCNPC), and the panel shares their personal approaches to treatment.

Raoul S. Concepcion, MD, FACS, poses polling questions for the audience’s medical specialty and the percent of patients they receive with prostate cancer.

“Completing those 4 injection cycles is likely to yield the best clinical outcomes for most of our patients,” says Matthew J. Ziegelmann, MD.

“[Out] of everything going on, this is probably 1 of the most exciting areas in prostate cancer,” says Jason M. Hafron, MD.

“There's a hope that we can modulate PSMA expression with some drugs, increase the amount of PSMA on the tumors, [and] therefore increase the amount of radiation that we can target,” says Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS.

"It depends on how you're paid and the structure of the compensation model," says Jennifer Miles-Thomas, MD, FPMRS.

“Men do well and they don't have a really high risk of outcomes that we don't want them to have and that patients don't want to have, which is really the need to catheterize,” says David A. Ginsberg, MD.

“Sepsis is real, and it's around 5%. I was surprised too, but this is what the actual data shows, and we should be aware of it,” says Ben H. Chew, MD, MSc.

“It's very clear that PSMA-PET imaging is having…a transformative impact on our ability to image metastatic disease, in that it is much more sensitive than we've had for the last 50 plus years—and also, 98% specific,” says Neil H. Bander, MD.

“I think as our understanding of mutations [and] our understanding the PARP inhibitors [grows], if the data pans out, we'll be using these earlier and earlier in patients, which I think we'll [will allow us to] see probably more benefit,” says Jason M. Hafron, MD.